

# Company Review

Dr Nina Webster  
CEO & Managing Director




# Forward looking statements

*This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.*

*Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.*


# Financial Year 2020/2021 achievements



# Development pipeline

4 product candidates in the pipeline, with 3 clinical opportunities

Compound	Disease Target	Preclinical	Phase 1	Phase 2	Pivotal Study	Market
DMX-200	Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients					
DMX-200	Focal Segmental Glomerulosclerosis (FSGS)					
DMX-200	Diabetic Kidney Disease					
DMX-700	Chronic Obstructive Pulmonary Disease (COPD)					
DMX-XXX	Undisclosed (multiple)					



# DMX-200 in Renal Overview

# DMX-200 clinical experience



## Phase 1 study (DMX-200-101)

- Healthy volunteers
  - Pharmacokinetic, metabolism & safety clinical study



## Phase 2a study (DMX-200-201)

- Chronic Kidney Disease
  - Safety and tolerability study, with efficacy endpoints included



## Phase 2a study (DMX-200-202)

- Focal Segmental Glomerulosclerosis
  - Safety and efficacy endpoints




## Phase 2 study (DMX-200-203)

- Diabetic kidney disease
  - Efficacy and safety endpoints

- Positive efficacy signal across all studies in renal disease
- Safe and well tolerated in healthy volunteers and renal patients
- DMX-200 compares favourably to compounds currently in development
- Compelling data in all studies collectively leading to DMX-200 future development

# Kidney disease intervention schematic



# DMX-200 market opportunity

Diabetic kidney disease



US market size 2018<sup>^</sup>  
**US\$5.8 billion**  
US: branded product:  
**US\$590/script**



Diabetic kidney disease is the  
**leading cause** of Chronic  
Kidney Disease Worldwide<sup>^</sup>



Diabetic patients that  
have kidney disease\*  
**40%**



Over 2 million  
scripts/year  
Addressable market  
over US\$1 billion

FSGS



Across all nephrotic syndromes,  
FSGS accounts for ‡

- 40% cases in **adult**
- 20% cases in **children**



30%-40% of FSGS transplant  
patients:  
FSGS **disease recurs** ‡




US incidence<sup>†</sup>  
**80,583**



US: average orphan:  
US\$7,000/month  
Addressable market  
over US\$1 billion






# DMX-200 in Acute Respiratory Distress Syndrome

## Overview

# Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS): an acute inflammatory lung process, which leads to:

- pulmonary oedema (excess fluid in the lungs)
- refractory hypoxemia (low level of oxygen in the blood)
- increased lung 'stiffness'
- impaired ability of the lung to eliminate carbon dioxide



Patients hospitalised with COVID-19: acute lung dysfunction due to human immune response to the virus

Likely to result in chronic lung fibrosis in many patients, leading to:

- poor quality of life
- high ongoing hospitalisation requirements
- poor prognosis

Pandemics have typically lasted 12-36 months

- Second COVID-19 wave globally anticipated
- Death rate associated with ARDS is high
- No known prevention of ARDS currently available

If successful, benefits of a treatment, using DMX-200, could extend well beyond the impact of COVID-19

# Acute Respiratory Distress Syndrome (ARDS)

## in COVID-19 patients – awarded \$1 million from AUS Government




REMAP-CAP: global WHO endorsed clinical study; >200 clinical sites in 16 countries\*



Study targets patients with Acute Respiratory Distress Syndrome (ARDS) as a result of a pandemic\*



REMAP-CAP/COVID-19 study protocol to include DMX-200



New renin-angiotensin system study domain approved by International Steering Committee



REMAP-CAP has been designated by the WHO as a Pandemic Special Study\*  
translation of clinical trial results occur directly with policymakers & public health officials for rapid implementation globally



REMAP-CAP is supported and funded by a consortium of government and non-government organisations\*



Results generated from REMAP-CAP during a declared pandemic can provide a collaborative pathway to global clinical practice\*



DMX-200 selected based on overwhelming scientific rationale & unique potential to treat COVID-19 related issues  
(supported by multiple peer-reviewed publications over the past month^)



# DMX-700 in Chronic Obstructive Pulmonary Disease

## Overview

# COPD landscape

## Global Initiatives

- World Health Organization (WHO)
- COPD Foundation
- American Thoracic Society
- Centers for Disease Control & Prevention (CDC)
- National Institute of Health (NIH)

All working towards raising COPD awareness in the population

### 2018 – FDA Guidance:

- Significantly shorter clinical trial size and duration required
  - Hard endpoints versus surrogate endpoints
  - Endpoints in weeks not years

Global COPD treatment market US\$14 billion (2017) & projected to increase at CAGR >4% to 2026

Asia Pacific expected to be fastest growing COPD market at CAGR ~8.7%

No candidates in late stage development

COPD is responsible for \$72 billion/year in direct healthcare expenditures in US


No cures available & existing treatments aimed at relieving symptoms only



# DMX-700 overview

DMX-700: oral administration candidate:

- Two molecules working together, each with an established safety profile
- Dimerix has completed initial studies on receptors involved in COPD
- Certain lung cells express multiple receptors, thus blocking only one receptor does not block signalling and results in only a partial response to treatment
- **DMX-700 blocks both receptors simultaneously to provide a complete response to treatment**
- Compelling data encouraged Dimerix to progress candidate towards clinical development





Dimerix

Financial Outcomes &  
Value Driving Events

# FY2020 Financial Outcomes

Cash Reserves  
at June 2020  
\$7.8 million

FY2020 net  
operating cash  
expenditure  
\$4.7m

R&D investment  
costs  
increased

\$2,445,350

2018

\$2,837,027

2019

R&D Investment

\$5,537,528

2020

Corporate/  
Administration  
costs decreased

\$1,418,810

2018

\$1,265,441

2019



Other Operating Costs

\$1,251,581

2020




# Corporate Snapshot (ASX:DXB)



Top 10 shareholders			
Position	Holder Name	Holding	% Holding
1	MR PETER FLETCHER MEURS	25,529,309	13%
2	BAVARIA BAY PTY LTD	7,316,992	4%
3	YODAMBAO PTY LTD	6,312,603	3%
4	MR JAMES JOSEPH CAMILLERI	2,400,000	1%
5	PFLEGER FAMILY A/C	2,105,988	1%
6	TOROHA PTY LTD	2,044,932	1%
7	JAMPASO PTY LTD	1,778,742	1%
8	MR RICHARD STANLEY DE RAVIN	1,700,000	1%
9	DR DAVID KENNETH PACKHAM	1,689,391	1%
10	CITICORP NOMINEES PTY LIMITED	1,594,245	1%



# 2020/2021 value driving events



# DIMERIX

End of Presentation

